Compare Vanguard High Dividend Yield ETF (VYM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard High Dividend Yield ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard High Dividend Yield ETF trades at $166.24, while Zimmer Biomet Holdings Inc trades at $95.27 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Vanguard High Dividend Yield ETF pays none, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| VYM | ZBH | |
|---|---|---|
52-Week High | $166.14 | $107.71 |
52-Week Low | $136.63 | $79.58 |
Market Cap | — | $18.55B |
Sector | — | Health |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYM trades at $166.36, up 0.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on high dividend yield stocks, offering income appeal, though key valuation ratios like P/E and P/B are not available. Recent news highlights institutional position adjustments and discussions on its role in retirement income portfolios.
Outlook is mixed: technical indicators suggest near-term caution due to overbought conditions, while the dividend strategy supports long-term income. Risks include market volatility and yield compression. Analyst sentiment is generally positive for income-focused investors, but monitor for pullbacks.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
